Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NNVC Stock Forecast 2025-2026
$1.30
Current Price
$20.65M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NNVC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
NNVC Price Momentum
0.0%
1 Week Change
+17.1%
1 Month Change
-31.2%
1 Year Change
-9.1%
Year-to-Date Change
-63.8%
From 52W High of $3.59
+38.3%
From 52W Low of $0.94
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching NanoViricides (NNVC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NNVC and similar high-potential opportunities.
Latest NNVC Stock Price Targets & Analyst Predictions
NNVC has shown a year-to-date change of -9.1% and a 1-year change of -31.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for NNVC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NNVC Analyst Ratings
0
Buy
0
Hold
0
Sell
NNVC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.30
Latest NNVC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NNVC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2024 | EF Hutton | Tim Moore | Buy | Reiterates | $6.50 |
| Feb 16, 2024 | EF Hutton | Tim Moore | Buy | Reiterates | $6.50 |
| Jun 1, 2023 | EF Hutton | Constantine Davides | Buy | Assumes | $5.25 |
| Apr 18, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $5.25 |
| Feb 28, 2023 | EF Hutton | Constantine Davides | Buy | Maintains | $5.25 |
Nanoviricides Inc. (NNVC) Competitors
The following stocks are similar to NanoViricides based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nanoviricides Inc. (NNVC) Financial Data
Nanoviricides Inc. has a market capitalization of $20.65M with a P/E ratio of -1.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -82.0%.
Valuation Metrics
Market Cap
$20.65M
Enterprise Value
$16.69M
P/E Ratio
-1.9x
PEG Ratio
-2.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+19.5%
Current Ratio
3.4x
Debt/Equity
0.0x
ROE
-82.0%
ROA
-47.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Nanoviricides Inc. (NNVC) Business Model
About Nanoviricides Inc.
What They Do
Develops antiviral therapeutics using nanotechnology.
Business Model
Nanoviricides Inc. focuses on creating antiviral nanomedicine, known as 'nanoviricides', that specifically target and neutralize virus particles. The company aims to meet unmet medical needs by providing effective treatments for viral diseases, particularly where options are limited or non-existent.
Additional Information
Operating at the intersection of biotechnology and healthcare, Nanoviricides Inc. is positioned to contribute significantly to public health and address challenges associated with future pandemics and viral outbreaks. Their innovative approach is aligned with the growing trend towards precision medicine, making them a noteworthy player in the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Dr. Anil R. Diwan Ph.D.
Country
United States
IPO Year
2005
Website
www.nanoviricides.comNanoviricides Inc. (NNVC) Latest News & Analysis
Latest News
Quick Summary
NanoViricides received ethics committee approval in the DRC to advance its Phase II trial of antiviral drug NV-387 for Mpox, enabling them to submit a full clinical trial application.
Why It Matters
Approval for the Phase II trial of NV-387 positions NanoViricides to advance its antiviral treatment for Mpox, potentially enhancing its market value and investor interest amid ongoing disease concerns.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
NanoViricides, Inc. (NYSE American: NNVC) will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City.
Why It Matters
NanoViricides' participation in a significant conference highlights its visibility and credibility, potentially attracting investors and partnerships, which could impact stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
NanoViricides (NYSE-A:NNVC) is developing a measles treatment amid rising infections and declining vaccinations. They have propagated the virus and are set to begin animal testing for their drug NV-387.
Why It Matters
NanoViricides' advancement in measles drug development amid rising infections highlights potential market demand and investment opportunities in biotech, especially for antiviral treatments.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
NanoViricides, Inc. (NYSE Amer.: NNVC) announced updates on its Measles drug development program, focusing on broad-spectrum antivirals using host-mimetic nanomedicine technology.
Why It Matters
NanoViricides' progress in its Measles drug development could signal advancements in antiviral treatments, potentially impacting its stock price and attracting investor interest in biotech innovations.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
NanoViricides (NYSE-A:NNVC) is evaluating its clinical-stage antiviral NV-387 for measles treatment, addressing a gap in approved therapies for the disease.
Why It Matters
NanoViricides' NV-387 could fill a significant gap in measles treatment, potentially driving demand and revenue, impacting stock performance positively.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
NanoViricides, Inc. (NYSE Amer.: NNVC) has initiated clinical evaluation of its antiviral drug NV-387 for treating the Measles virus, utilizing host-mimetic nanomedicine technology.
Why It Matters
NanoViricides' evaluation of NV-387 for Measles could signify a breakthrough in antiviral treatments, potentially boosting market confidence and impacting stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About NNVC Stock
What is Nanoviricides Inc.'s (NNVC) stock forecast for 2025?
Analyst forecasts for Nanoviricides Inc. (NNVC) are not currently available. The stock is trading at $1.30.
Is NNVC stock a good investment in 2025?
Analyst ratings for NNVC are not currently available. The stock is currently trading at $1.30. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NNVC stock?
Price predictions from Wall Street analysts for NNVC are not currently available. The stock is trading at $1.30.
What is Nanoviricides Inc.'s business model?
Nanoviricides Inc. focuses on creating antiviral nanomedicine, known as 'nanoviricides', that specifically target and neutralize virus particles. The company aims to meet unmet medical needs by providing effective treatments for viral diseases, particularly where options are limited or non-existent.
What is the highest forecasted price for NNVC Nanoviricides Inc.?
Price targets from Wall Street analysts for NNVC are not currently available. The stock is trading at $1.30.
What is the lowest forecasted price for NNVC Nanoviricides Inc.?
Price targets from Wall Street analysts for NNVC are not currently available. The stock is trading at $1.30.
What is the overall NNVC consensus from analysts for Nanoviricides Inc.?
Analyst ratings for NNVC are not currently available. The stock is trading at $1.30.
How accurate are NNVC stock price projections?
Stock price projections, including those for Nanoviricides Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 4:03 PM UTC